Lifecore Biomedical, Inc. (LFCR)
(Real Time Quote from BATS)
$4.99 USD
+0.14 (2.89%)
Updated Jul 22, 2024 11:06 AM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LFCR 4.99 +0.14(2.89%)
Will LFCR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LFCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LFCR
Lifecore (LFCR) Down 30% on Ending Strategic Review With No Deal
Strength Seen in Lifecore Biomedical (LFCR): Can Its 16.0% Jump Turn into More Strength?
LFCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vanda Pharmaceuticals (VNDA) Reports Break-Even Earnings for Q3
Will Lifecore Biomedical (LFCR) Report Negative Q1 Earnings? What You Should Know
Lifecore Biomedical (LFCR) Reports Q4 Loss, Tops Revenue Estimates
Other News for LFCR
Laughing Water Capital Q2 2024 Letter
Enzo Biochem: Is This Time Finally Different?
Lifecore Biomedical: No Sale Soon Amidst Leverage And Uncertainty
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Graham & Doddsville Spring 2024 Newsletter From Columbia Business School